NYSE · SERVICES-MEDICAL LABORATORIES · LARGE CAP
Labcorp Holdings Inc. LH
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$14.0B
▲ 7.2% vs FY2024
EPS · FY25
$10.46
Dividend / sh · FY25
$2.88
Payout · FY25
27%
ROE · FY25
10.5%
Net margin · FY25
6.3%
Dividend coverage
3.6×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 14.0B
Revenue, FY2025 · full 19-year series below
Revenue
Net income
6 cents of every revenue dollar became profit this year.
Per share
USD 10.46
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 3.6 times — the rest stayed in the company.
Profitability
10.5%
Return on equity, FY2025
ROE
Operating margin9.9%
Net margin6.3%
Return on assets4.8%
Each USD of equity produced 11 cents of profit this year.
Returned to shareholders
USD 688.2M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 240.7M
Net buybacksUSD 447.5M
Share of profit78.5%
Consecutive raises—
USD 240.7M in dividends and USD 447.5M in buybacks — 79% of the year's profit went back to shareholders.
Growth
−0.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.6%
−0.0%
+4.9%
+7.1%
Net income
−11.8%
−10.8%
+7.2%
+3.1%
EPS, diluted
−9.2%
−8.0%
+9.2%
+4.6%
Dividend / share
+10.1%
Returned to shareholders
−18.9%
+52.8%
+4.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.08B
Shares outstanding, FY2025
Change, 5 years−14.2%
Change, 10 years−18.9%
The share count shrank 14% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 18.4B
total assets, end of FY2025
Total assetsUSD 18.4B
EquityUSD 8.6B
CashUSD 532.3M
Gross debtUSD 5.6B
Net debtUSD 5.1B
Current ratio1.42×
Net debt stands at 59% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
14.0
13.0
12.2
11.9
13.1
14.0
11.6
11.3
10.3
9.6
8.7
6.0
5.8
5.7
5.5
5.0
4.7
4.5
4.1
Operating income $B
1.4
1.1
0.7
1.4
3.0
2.4
1.3
1.3
1.3
1.3
1.0
0.9
1.0
1.0
0.9
1.0
0.9
0.8
0.8
EBITDA $B
2.1
1.7
1.3
2.0
3.6
3.1
1.9
1.9
1.8
1.8
1.5
1.2
1.2
1.3
1.2
1.2
1.1
1.0
0.9
Income tax $B
0.2
0.2
0.2
0.2
0.7
0.7
0.3
0.4
−0.2
0.4
0.3
0.3
0.3
0.4
0.3
0.3
0.3
0.3
0.3
Net income $B
0.9
0.7
0.4
1.3
2.4
1.6
0.8
0.9
1.2
0.7
0.4
0.5
0.6
0.6
0.5
0.6
0.5
0.5
0.5
EPS, diluted $
10.46
8.84
4.77
13.97
24.39
15.88
8.35
8.61
11.81
6.82
4.35
5.91
6.25
5.99
5.11
5.29
4.98
4.16
3.93
Dividend / sh $
2.88
2.88
2.88
2.16
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
27
33
61
15
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
10.5
9.4
4.7
12.6
24.1
18.2
11.2
12.8
19.9
13.6
11.3
19.2
15.4
15.7
20.9
24.4
28.6
27.2
27.6
Shares out B
0.08
0.08
0.08
0.09
0.09
·
0.10
0.10
0.10
0.10
0.10
0.08
0.09
0.09
0.10
0.10
0.11
0.11
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
73 of 73
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed